$KZR
Kezar Life Sciences Inc
PRICE
$6.63 ▲10.133%
Last Close
VOLUME
1,336,727
DAY RANGE
5.575 - 6.1
52 WEEK
4.61 - 18.55
Key Metrics
Market Cap
363.70 M
Beta
0.77
Avg. Volume
1.30 M
Shares Outstanding
60.42 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-11
Next Dividend Date
Company Information
Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.
CEO: John Fowler
Website: kezarlifesciences.com
HQ: 4000 Shoreline Ct Ste 300 South San Francisco, 94080-2005 California
Related News